NovaBridge Biosciences（NBP）内部人交易：高管与董事近期交易
过去 18 个月，共有 5 位内部人为 NovaBridge Biosciences（NBP）报告了 16 笔 Form 4 交易（最近一笔 2026-09-21）。
| 日期 | 内部人 | 职务 | 类型 | 股数 | 市值 |
|---|---|---|---|---|---|
| 2026-09-21 | Dennis Phillip Andrew | Chief Medical Officer | 卖出 | 8,209 | $5,828 |
| 2026-09-21 | Dennis Phillip Andrew | Chief Medical Officer | 买入 | 23,695 | $0 |
| 2026-09-11 | Cao Sean Wuxiong | Chief Bus. Development Officer | 卖出 | 107,978 | $79,904 |
| 2026-09-08 | Cao Sean Wuxiong | Chief Bus. Development Officer | 买入 | 235,136 | $0 |
| 2026-09-08 | Cao Sean Wuxiong | Chief Bus. Development Officer | 买入 | 104,236 | $0 |
| 2026-09-01 | Xu Cong Claire | EVP, Clinical Development | 买入 | 9,382 | $0 |
| 2026-09-01 | Xu Cong Claire | EVP, Clinical Development | 卖出 | 3,282 | $2,593 |
| 2026-08-25 | Lenz Robert A. | 董事 | 买入 | 17,218 | $0 |
| 2026-07-07 | Xu Cong Claire | SVP, Clinical Development | 买入 | 12,432 | $0 |
| 2026-07-07 | Xu Cong Claire | SVP, Clinical Development | 卖出 | 4,485 | $3,992 |
| 2026-06-22 | Dennis Phillip Andrew | Chief Medical Officer | 买入 | 23,695 | $0 |
| 2026-06-22 | Dennis Phillip Andrew | Chief Medical Officer | 卖出 | 8,494 | $5,606 |
| 2026-06-02 | Xu Cong Claire | SVP, Clinical Development | 买入 | 9,382 | $0 |
| 2026-06-02 | Xu Cong Claire | SVP, Clinical Development | 卖出 | 3,494 | $13,766 |
| 2026-05-18 | Cao Sean Wuxiong | Chief Business Development Officer and Director | 卖出 | 21,399 | $42,584 |
| 2026-04-28 | Hagler Mark Arnold | President and Chief Commercial Officer | 买入 | 230,000 | $577,300 |
来源：SEC Form 4 申报文件 · 截至 2026-09-21